Antisense oligodeoxynucleotides (ODNs) possess great potential as sequence-specific therapeutic agents. Sufficient concentrations of intact ODN must bypass membrane barriers and access the cytosol and nucleus, for ODNs to be therapeutically effective. A cytosolic delivery strategy was designed to improve the efficiency of ODN delivery in bone-marrow-derived macrophages. This liposome-based formulation utilizes listeriolysin O (LLO), the endosomolytic hemolysin from Listeria monocytogenes, to mediate the escape of ODN from endocytic compartments into the cytosol. To monitor the cytosolic delivery of ODN, subcellular trafficking of fluorescently labeled ODNs was visualized using epifluorescence microscopy. The expression of target protein and mRNA after delivery was measured using flow cytometry and Northern blot analysis, respectively. ODN specific for murine intercellular adhesion molecule-1 (ICAM-1) encapsulated in LLO-liposomes was released to the cytosol and trafficked to the nucleus, efficiently and specifically suppressing activation-induced expression of ICAM-1 at both protein and mRNA levels. Delivery without LLO resulted in sequestration of ODN in vesicular compartments leading to little inhibition of ICAM-1 expression, which supports the requirement of LLO for efficient cytosolic delivery using this system. The data clearly demonstrate that LLO-mediated escape of ODN from intracellular vesicles is an effective approach to achieve full therapeutic antisense activity in cultured macrophages.
Introduction
Antisense oligonucleotide therapy offers a unique therapeutic approach to combating a wide range of diseases and immunological disorders such as viral infections, cancer, chronic inflammation, and transplant rejection. 1 Conventional pharmaceuticals treat these disorders with varying degrees of success by modulating the function of the protein at the receptor level. In contrast, antisense oligodeoxynucleotides (ODNs) have a unique advantage over conventional pharmaceuticals in that they alter the disease state at an upstream level in gene expression and modulate the magnitude of transcription and translation of the particular target gene. ODNs specifically target and exert their activity by hybridizing with their complementary sense strands located in the cytosol and nucleus. The unique advantages afforded by antisense therapy provide the impetus for further research in developing ODN formulations for clinical use.
To realize the full potential of antisense ODNs, therapeutic concentrations of functionally intact ODN must be transported across many barriers to their intracellular sites of action. The cell and endosomal membranes are physical barriers, which impede effective concentrations of ODN from reaching their subcellular targets within the cytosol and nucleus. ODNs, which are macromolecular and polyanionic in nature, have extremely low membrane permeability and do not readily diffuse across biological membranes. 2, 3 In most cell culture-based experiments, ODNs are internalized and predominantly sequestered in the endolysosomal compartments where they are eventually degraded, but low levels may leak into the cytosol. 4 Upon cytosolic access, ODNs tend to rapidly translocate to the nuclear compartment. [5] [6] [7] Many studies utilizing ODNs in simple saline solution have shown variable levels of antisense effect, both in vitro and in vivo. In some cases, ODNs may localize to the cytosol and nucleus successfully exhibiting antisense effects, [8] [9] [10] [11] [12] while sequestration of ODN in endolysosomal compartments has been observed in other cases potentially resulting in reduced efficacy. 13 The mixed results obtained when using ODN solutions in vitro can be attributed in part to the different cell types, which vary greatly in their capacity to internalize and deliver ODN to the cytosol. 8, [14] [15] [16] Considering the potential barriers preventing therapeutic concentrations of ODNs from accessing their target sites and the disparate uptake and transport of ODNs to the cytosol depending on cell type, the development of a targeted and more efficient cytosolic delivery system is necessary for augmenting the amount of drug reaching the cytosol and for enhancing antisense effects. 3 A number of ODN delivery strategies, under current investigation and development, focusing on enhancing cellular uptake and improving delivery into the cytosolic space, include cationic and pH-sensitive liposomes, cationic polymeric particles such as polyethylenimine and polyamidoamine dendrimers, membrane penetrating peptides, and pore-forming proteins (for recent reviews on ODN delivery strategies, refer to Juliano et al 3 and Lebedeva and Stein 4 ). Although these strategies resolve some of the issues associated with delivering ODNs to the cytosol with varying degrees of success, their suboptimal antisense efficacy and other inherent limitations, including nonspecific effects, cell toxicity, and incompatibility with the serum-containing in vivo environment, still remain. 3, 4 For efficient delivery of ODNs to the cytosol and nucleus of bone-marrow-derived macrophages, a simple formulation utilizing moderately effective pH-sensitive liposomes combined with the endosomolytic protein listeriolysin O (LLO) has been developed and tested. This system improves the efficiency of liposomal delivery in vitro and has the potential to improve currently available delivery modalities. The development of this system is based upon the prior success of utilizing LLO-containing liposomes to deliver proteinaceous macromolecules to the cytosolic space of macrophages both in vitro and in vivo. 17, 18 In this report, LLO, the cytolysin derived from the Gram-positive facultative intracellular bacteria, Listeria monocytogenes, is utilized as an essential component of the delivery system for increasing the efficiency of cytosolic delivery of ODNs. Within the endosome, LLO is hypothesized to be released from the destabilized pH-sensitive liposomes and exert its endosomolytic activity by perforating the endosome, thus mediating the escape of ODNs from the endosome into the cytosol. LLO is unique among the thiol-activated pore-forming hemolysins in that it exhibits higher activity in the acidic endosomal environment 19, 20 and contains a 19 amino-acid long, PEST-like sequence in the N-terminus, 21 which could signal phosphorylation-mediated rapid degradation of LLO. The pH-dependent activity in combination with the rapid cytosolic degradation of LLO minimizes potential cytotoxic effects. Therefore, these properties make LLO an ideal agent to be used in conjunction with pHsensitive liposomes for efficient intracellular delivery of ODNs via endosomal disruption with minimal cytotoxicity.
To test our hypothesis that LLO enhances cytosolic delivery, a model phosphorothioate ODN specific against murine intercellular adhesion molecule 1 (ICAM-1; CD54) was utilized. The ICAM-1 molecule is a cell surface glycoprotein constitutively expressed at low levels on both nonhematopoietic and hematopoietic cells including tissue macrophages and lymphocytes. 22 The expression of ICAM-1 is typically upregulated in the presence of cytokines and other inflammatory mediators such as interleukin-1, tumor necrosis factor, interferon-g, and lipopolysaccharides, 23 which recruits various immune cells such as T cells, B cells and antigen-presenting cells to the site of inflammation and enhances antigenmediated T cell activation response. 24 Therefore, increased ICAM-1 expression plays an important role in the pathophysiology of various immune-related disorders including inflammatory disorders and allogenic organ transplant rejection. [25] [26] [27] Among many existing strategies to improve immune regulation by blocking the function of ICAM-1, antisense ODNs targeted against ICAM-1 serve as an ideal candidate drug in inhibiting the induced overexpression of ICAM-1 in many disorders. [28] [29] [30] [31] In this report, we assess the ability of LLO-liposomes to deliver ODNs specific against murine ICAM-1 to the cytosol of bone marrow-derived macrophages in primary cultures. We hypothesize that LLO-containing pHsensitive liposomes first destabilize in the acidic environment of the endosome, as depicted in step 3 of Figure 1 based on evidence from our previous studies on LLOliposomes. 17, 18, 32 The liposomal contents, LLO and ODNs, are then presumably released into the endosome, whereupon LLO disrupts the endosomal membrane allowing ODNs to enter the cytosol (step 4, Figure 1 ). In addition to demonstrating our delivery strategy, this report evaluates the duration of antisense effect postdelivery. We compare three formulations for the delivery of ODNs: LLO-liposomes, liposomes without LLO, and solutions of free ODNs. The cytosolic and nuclear trafficking of fluorescently labeled ODNs was monitored along with the evaluation of antisense effect of ODNs by measuring the expression of the target protein and mRNA after ODN delivery. Our observations clearly indicate that LLO dramatically enhances the efficient delivery of antisense ODNs to the cytosol and nucleus of macrophages in order to abrogate the overexpression of ICAM-1 protein and mRNA.
Results
Characterization of LLO-liposomes containing murine ICAM-1 antisense oligonucleotides LLO-containing pH-sensitive liposomes were characterized and developed as a vehicle to efficiently deliver therapeutic concentrations of antisense ODNs to the cytosol of cells. Important characterization properties measured include the following: liposomal size, ODN encapsulation efficiency, LLO encapsulation efficiency, and LLO pore-forming activity. The mean diameter of liposomes extruded through 0.2 mm polycarbonate filters was determined by quasi-elastic light scattering to be 200730 nm through intensity and volume weighted analyses. The encapsulation efficiency of LLO inside liposomes, ranged from 10 to 30%, as determined by quantitative PAGE, whereas 4-8% of ODN was typically encapsulated inside liposomes following removal of unencapsulated LLO and ODN by gel filtration. No significant change in ODN encapsulation efficiency was observed between LLO-and non-LLO-liposomes. A hemolysis assay performed on LLO released from liposomes showed no reduction in the functional activity of LLO after encapsulation. The liposomal formulations did not induce significant cytotoxicity in murine bone marrow-derived macrophages as determined by morphological assessment as well as by lactate dehydrogenase (LDH) release-based cytotoxicity assay. The cytotoxicity was calculated as a percentage of the total LDH release (100%), which is the sum of the LDH release measured at each of the four separate intervals: prior to liposomal treatment, after liposomal treatment, after chase, and after Triton-induced lysis. In comparison to untreated cells (0% total LDH release), the LDH release from the cells after treatment and chase was 0.5%70.1 The delivery of ODN to the cytosol and nucleus was assessed by visualizing the subcellular distribution of carboxyfluorescein-labeled ODNs and Texas Red-labeled dextrans using fluorescence microscopy. Based on reported studies showing rapid transport of microinjected ODN from the cytosol to the nucleus, 5, 6 we tested our hypothesis that ODNs encapsulated in LLO-liposomes will be efficiently delivered from the endosome to the cytosol and then be shuttled to the nucleus. For each treatment, a high molecular weight dextran (70 kDa) was employed to verify that the integrity of the nuclear membrane remained intact after liposomal delivery with or without LLO. The 70 kDa dextran molecules monitored by 570 nm excitation wavelength were unable to freely diffuse through the nuclear pores and thus remained in the cytoplasmic compartment and were excluded from the nuclear space (Figure 2 a3, b3, c3, d3) .
The phase contrast images, fluorescein excited at 490 nm images and Texas Red excited at 570 nm images were overlaid to compare the subcellular distribution of ODNs and dextrans (Figure 2 a4 , b4, c4, d4). After 2 h incubation, ODNs delivered in LLO-containing liposomes were preferentially localized in the nucleus and distributed in the cytosolic spaces (Figure 2 a2 ), while the dextrans were quarantined in the cytoplasmic region (Figure 2 a3) . In contrast to the delivery attained by LLOcontaining liposomes, ODNs delivered in liposomes without LLO showed punctate cytoplasmic staining and remained undetected in the nucleus, after 2 h incubation (Figure 2 b2) . Similarly, dextrans delivered in liposomes without LLO, exhibited bright punctate vesicular staining and remained excluded from the nucleus (Figure 2 b3 ). We also investigated the effect of prolonged incubation on subcellular distribution using liposomes with or without LLO. Cells pulsed with ODNs in LLO-containing liposomes for 7 h exhibited bright and increased nuclear staining with reduced cytoplasmic vesicular staining (Figure 2 c2 ). Conversely, ODNs delivered in liposomes without LLO showed bright cytoplasmic punctate staining with little or no nuclear staining (Figure 2 d2 ). ODN accumulation in the nucleus was consistently observed predominantly in the cells treated with LLO-containing liposomes.
Time course of ICAM-1 protein and mRNA expression upon activation
Prior to determining the efficacy of ODNs delivered in LLO-liposomes for inhibiting the activation-induced overexpression of ICAM-1, we first established the duration of cell activation required to achieve the full induction of ICAM-1 protein and mRNA. Flow cytometry and cellular ELISA were used to monitor the cell surface expression level of ICAM-1 protein in bone marrow-derived macrophages as a function of activation time. The specific level of ICAM-1 mRNA was detected by Northern blot hybridization. The basal expression level of ICAM-1 protein was low, but ICAM-1 levels progressively increased with longer activation times in the presence of LPS and IFN-g, peaking at around 8 -12 h (Figure 3a) . The mean fluorescence intensity (MFI) of the 
Inhibition of ICAM-1 mRNA by oligonucleotide encapsulated in LLO-liposomes
In order to confirm that the inhibition of ICAM-1 protein expression demonstrated in Figure 4 was a direct result of ODNs exerting an antisense effect on specific mRNA upon delivery to the cytosol, we monitored the induced levels of ICAM-1 mRNA after delivery of ODN using various formulations. Encapsulation of ODNs in LLOliposomes dramatically reduced the ICAM-1 mRNA level as compared to free ODN solution or ODNs delivered in liposomes without LLO. In Figure 5 , ICAM-1 mRNA level of macrophages activated for 2 h without ODN treatment is denoted as 100%, while the . MFI values were normalized such that the differences between basal levels and fully induced levels equal 100. Differences between treatments were tested for significance by Wilcoxon ranksum test (*Pr0.05).
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Oligonucleotide dose response relationship to ICAM-1 mRNA levels
Experiments were performed to determine the dose dependency of ICAM-1 mRNA inhibition with ODN delivered in LLO-liposomes. The extent of mRNA suppression was monitored by Northern blot analysis in cells that were treated with ODNs ranging from 0 to 0.5 mM concentration. Treatment at 0.03 mM ODN in LLOliposomes reduced the expression of ICAM-1 by at least 66%, and at 0.5 mM reduced the expression close to 93%, with clear indications of dose dependency at ODN concentrations within the range tested ( Figure 6 ). Cells that were treated with LLO-liposomes containing no ODN showed no reduction of induced ICAM-1 mRNA levels ( Figure 6 ).
Duration of antisense effect
The stability and persistence of antisense activity of ODNs delivered in LLO-containing liposomes was determined and the half-life of the delivered drug estimated. After pulsing cells with 0.5 mM ODN encapsulated in LLO-liposomes, cells were washed and chased up to 48 h before activation in order to determine the half-life of the antisense effect in the cytosol as measured by monitoring ICAM-1 mRNA recovery. After 6 h chase, cells expressed less than 5% of the fully induced ICAM-1 mRNA levels ( Figure 7) . However, after 24 h chase time, the ICAM-1 mRNA level rebounded back to 36%, and after 48 h chase returned to 93% of the fully activated ICAM-1 mRNA level, which allowed for the estimation of the persistency of antisense ODN once delivered in the cytosol ( Figure 7 ). 6) was compared to the ICAM-1 mRNA levels in the untreated, unactivated, and activated controls (lanes 7 and 8). Cells were treated with 0.5 mM ODNs in LLO-liposomes for 2 h, washed, and chased for different times: (1) 1 h, (2) 2 h, (3) 4 h, (4) 6 h, (5) 24 h, and (6) 48 h after delivery and before activation. Conditions in lanes 7 and 8 are the same as those in 7 and 8 in Figure 5 . All ICAM-1 mRNA levels are normalized against GAPDH levels.
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Discussion
In this report, LLO-liposomes are utilized to successfully transport functionally active ODNs to their cytosolic target site by circumventing the endosomal membrane barriers. In contrast, the majority of ODNs delivered in solution form or in liposomes without LLO are predominantly shuttled into the endocytic compartments, sequestered and degraded in the endosomes and lysosomes. Our experimental design is to monitor the reduction of induced ICAM-1 expression in bone marrow-derived macrophages using ODNs in different formulations, thus demonstrating the efficiency and utility of LLO-liposomes as a cytosolic delivery platform for nucleic acid-based macromolecular drugs. Several early in vitro studies show that depending on cell type, incubation with high concentration of ODN solution for prolonged periods can elicit an antisense response. 8, 33 Irrespective of the effectiveness of naked ODNs, it should be considered that administration of phosphorothioate ODN solution in vivo results in a circulation half-life ranging from 20 to 60 min. 15, 34 The ODNs are typically cleared rapidly from the plasma and are predominantly taken up by highly perfused organs such as the kidney and liver where the tissue half-life ranges between 2 and 19 days depending on the ODN chemistry and dose. 14, 16, 35, 36 The pharmacokinetics of ODN can be readily modified upon encapsulation inside liposomes and prolonged with the use of long-circulating liposomes, although it is not an easy task to maintain high concentrations of ODN near target cells for an extended period. Thus, in order to emulate the in vivo scenario of targeting macrophages accessible from the bloodstream, all in vitro experiments in this report were performed using bone marrow-derived macrophages pulsed with ODN in three different delivery formulations in the presence of serum for a short duration, typically only 2 h. Primary cultured macrophages were used in this study, since it is well documented that macrophages expressing elevated levels of ICAM-1 protein upon activation play an important role in the pathophysiology of immune-and inflammation-related disorders. 23 Macrophages incubated with high concentrations of naked ODNs in solution exhibited negligible change in the induced ICAM-1 protein expression and elicited minimal reduction of ICAM-1 mRNA levels. Furthermore, increasing the dose of naked ODNs by 100-fold did not significantly improve the reduction of ICAM-1 mRNA levels. These results are consistent with the results observed by Bennett et al 7 comparing uptake of naked ODNs with those delivered by cationic lipids. The data suggest the existence of definitive limiting steps for ODN uptake and transport to the cytosol in cultured cells, seemingly because of the potential saturation of receptor-mediated endocytosis and inability of the endocytosed ODN to escape lysosomal degradation. 15, 37 Increasing the concentration of naked ODN pulsed to the cell by 100-fold slightly lowered ICAM-1 mRNA levels, while no reduction in cell surface ICAM-1 protein expression was observed using the same dose. In our experiments, we observed that minimal reduction in mRNA levels did not lead to any detectable reduction in ICAM-1 protein. However, a correlation between ICAM-1 mRNA and protein downregulation was observed when significantly higher levels of mRNA suppression was achieved with ODN delivery using LLO-liposomes. The data lead us to suggest that a threshold exists for ICAM-1 mRNA reduction below which a decrease in ICAM-1 mRNA does not directly translate to ICAM-1 protein downregulation. Therefore, delivering high concentrations of ODNs to the cytosol must be achieved in order to observe a therapeutic antisense response. Furthermore, targeted cytosolic delivery is shown to be critical and more effective than merely increasing the ODN concentration in the vicinity of the cell.
ODNs delivered in pH-sensitive liposomes without LLO were unable to significantly downregulate the expression of ICAM-1. This does not dispute with the reported advantages of the 'pH-sensitive' liposomes, but rather points out relatively low efficiency in cytosolic delivery of macromolecules 38 when pH-sensitive liposomes do not carry an additional endosomolytic mechanism for release into the cytosol such as that provided by LLO in our study.
ODNs delivered in LLO-liposomes effectively inhibited the activation-induced expression of both ICAM-1 protein and mRNA, maintaining ICAM-1 expression at a level similar to that observed in unactivated cells. The data definitively show that LLO incorporated in our liposomal delivery system plays an important prerequisite role in enhancing the cytosolic delivery efficiency and thereby improving the antisense activity observed in bone marrow-derived macrophages. The antisense effects observed upon cytosolic delivery of murine ICAM-1-specific ODNs in LLO-liposomes in our study were target-specific, inhibiting the activation-induced expression of only ICAM-1 and not of IFN-b, another protein induced by activation in bone marrow-derived macrophages. Furthermore, scrambled sequence and human ICAM-1 sequence-specific control ODNs delivered in LLO-liposomes did not block the induced expression of ICAM-1 protein and mRNA showing sequence-specific antisense effect. The reduction of ICAM-1 mRNA levels seen after delivering ICAM-1-specific ODNs using LLOliposomes suggests that the target mRNA is degraded most likely by RNase H-mediated hydrolysis, which is consistent with previous studies. 39 Inhibition of ICAM-1 protein and mRNA expression was compared for each of the formulations containing equal concentrations of ODN. ODN delivered in LLOliposomes significantly reduced both ICAM-1 protein and mRNA levels close to basal levels, whereas ODN delivered in liposomes without LLO and in free solution did not reduce ICAM-1 protein and mRNA to the same extent. These results correlate strongly with previous reports demonstrating the dependency of LLO in the cytosolic delivery of protein using LLO-liposomes 17, 18 and in the cytosolic invasion of bacteria by LLOmediated perforation of endosomes. 32 Visual confirmation by fluorescence microscopy further validates the requirement of utilizing LLOcontaining liposomes to efficiently deliver ODNs to the cytosol and nucleus, and the results correlate well with the pharmacological data in this report. The compilation of our results in Figures 2, 4 , and 5 complement each other to show a strong correlation between cytosolic and Antisense delivery using LLO-liposomes E Mathew et al nuclear localization of ODNs and LLO-mediated antisense activity as monitored by inhibition of target protein and mRNA levels using LLO-containing liposomes. Significant levels of dextrans delivered by LLO-liposomes seem to remain entrapped in vesicles as evidenced by bright vesicular staining. This could be because of the slow release of large 70 kDa dextrans through the LLO pore as well as the bright punctate fluorescence of the concentrated dextrans in a small volume that visually overwhelms the diffuse fluorescence in the cytosol. The escape efficiency of large molecules through the LLO pore in cell types other than macrophages as well as the in vivo efficacy of LLOmediated delivery for ODNs requires further study and characterization.
The pharmacological activity of ODNs is dependent not only on the amount and concentration of ODN delivered to the cytosol but also on the duration of ODN persistence within the cell. 40 Using fluorescence microscopy, Leonetti et al 6 visualized the presence of fluorescently labeled phosphorothioate ODNs in the nucleus 20 h after microinjection. Their study provides visual confirmation of the time that ODNs remain in the nucleus based on the assumption that fluorescence correlates with ODN stability; however, it does not correlate the presence of ODN in the cytosol to antisense activity. To the best of our knowledge, our report is the first to estimate the persistence of antisense activity by monitoring mRNA levels upon bolus administration of ODN into the cytosol using LLO-containing liposomes. Based on the recovery of activation-inducible mRNA levels in response to the reduction of functional ODN in the cell, we see that ODN delivered to the cytosol has a half-life of more than 24 h. Our results show slow and close to full recovery of activation-inducible mRNA levels during the 48 h chase period post-delivery. The estimated half-life of the phosphorothioate ODN determined in this report corresponds to the results observed by Dean and McKay 9 when monitoring the expression of PKC-a in murine C127 mammary epithelial cells after administration of murine phosphorothioate PKC-a ODNs using cationic liposomes. In further developing the formulation for clinical testing, it is critical to estimate the half-life of delivered ODN within cells in order to determine the frequency of ODN treatments necessary to maintain the downregulated expression of the target protein.
In conclusion, our results clearly show that LLOmediated cytosolic delivery using a liposomal platform is necessary and sufficient to engender full activity of antisense ODNs in cultured bone marrow-derived macrophages. Co-encapsulation of LLO and murine ICAM-1-specific ODNs inside pH-sensitive liposomes dramatically increased the delivery of ODNs to the cytosol, achieving ! 90% inhibition of the induced expression of both ICAM-1 mRNA and protein. LLOliposomes effectively breach the membrane barriers through endosomal lysis enabling sufficient concentrations of ODNs to be transported to the cytosol, allowing efficient and sequence-specific inhibition of ICAM-1 expression. The LLO-liposomal delivery system described and characterized in this paper for ODN delivery and persistent therapeutic effect offers a great potential to improve the cytosolic targeting of ODNs.
Materials and methods

Preparation of liposomes
Dried lipid films were made from a chloroform/ methanol mixture of 10 mmol egg phosphatidylethanolamine (PE, Avanti Polar Lipids, Inc.) and 5 mmol cholesteryl hemisuccinate (CHEMS, Sigma) using a Buchi Rotavapor. The lipid film was hydrated with ODNs (4.3 mg/ml), LLO (200 mg/ml), or a mixture of both in 10 mM HEPES, pH 8.5 buffer containing 140 mM NaCl. The resulting multilamellar vesicles were freeze-thawed four times and extruded through 0.4 mm pore size polycarbonate filters first (Nuclepore), and then through 0.2 mm pore size filters, four times each to control the size of liposomes to ensure uniformity. The mean diameters of the liposomal formulations were assessed by quasielastic light scattering using the Zeta Potential/Particle Sizer Nicomp 380 ZLS. After extrusion, liposomes were separated from the unencapsulated contents by size exclusion chromatography using a Sepharose CL-4B column (Amersham Pharmacia Biotech). Liposomes were stored under argon at 41C and used in experiments within 7 days after preparation. Encapsulation efficiencies of ODNs or LLO inside liposomes were determined by quantitative polyacrylamide gel electrophoresis and by measuring the intensities of the bands using MetaMorph Image Analysis software (Universal Imaging). To measure ODN encapsulation efficiency, liposomes were destabilized using 4% C 12 E 8 and the samples were resolved in a 15% Tris-Borate-EDTA (TBE) polyacrylamide gel (Bio-Rad). ODN concentration was determined by SYBR Green 1 (Molecular Probes Inc.) staining and calculated from a standard curve generated with known concentrations of ODNs ranging from 6.25 to 50 mg/ml. LLO encapsulation was measured similarly by SDS-PAGE followed by staining with Coomassie brilliant blue R-250 (Fisher Scientific) and calculated based on known concentrations of LLO ranging from 2.5 to 80 mg/ml.
Purification of LLO
Recombinant 6 histidine (his6)-tagged LLO was purified from the E. coli strain transformed with pET29b plasmid carrying the six histidine-tagged LLO cDNA, which was obtained from D Portnoy at the University of California, Berkeley. 41 Recombinant bacteria were cultured at 301C in LB medium containing kanamycin. Expression of LLO was induced by adding 1 mM isopropyl-b-D-thiogalactopyranoside (Gibco BRL) and incubating for an additional 4 h at 301C. The bacterial cell culture was pelleted and cells were disrupted twice using a French press (Thermo Spectronic). The bacterial lysate supernatant was adsorbed to Ni-NTA Superflow resin (Qiagen) and the his6-tagged LLO was eluted with buffer containing 500 mM imidazole and dialyzed overnight against 10 mM HEPES, 140 mM NaCl, pH 8.5. Purity of the recombinant LLO was analyzed by SDS-PAGE followed by Coomassie blue staining, concentration was measured by bicinchoninic acid (BCA) assay (Pierce), and each batch was tested for pore-forming activity by red blood cell (RBC) hemolysis assay.
Hemolysis assay
Hemolysis assays 18, 42 were performed on sheep RBCs washed in HEPES, pH 7.4 with 1 mM dithiothreitol to measure the pore-forming activity of LLO. Lysis of Antisense delivery using LLO-liposomes E Mathew et al 1 Â 10 8 RBC/ml by LLO was assayed by monitoring the change in 901 angle light scattering at 590 nm wavelength using a Spex Fluoromax-2 spectrofluorometer (Jobin Yvon-Spex Instruments S. A., Inc.). A sigmoidal decrease in right-angle scatter was observed indicating the lysis of RBCs upon addition of LLO to the suspension. The time required to achieve 50% lysis was used to determine the relative activity of the LLO protein.
Antisense oligonucleotides
All antisense ODNs used in this study were composed of 20 nucleotide bases with modified phosphorothioate backbones, generously provided by ISIS Pharmaceuticals Inc. ISIS 3082 (5 0 -TGCATCCCCCAGGCCACCAT-3 0 ) was designed to bind to its complementary sequence in the 3 0 -untranslated region of murine ICAM-1 mRNA. 10 12 ISIS 2302 with a sequence of 5 0 -GCCCAAGCTGG-CATCCGTCA-3 0 is designed to bind specifically to human ICAM-1 mRNA and does not exert any pharmacologic activity in mice. 43 Bone marrow-derived macrophage culture Bone marrow cells were extracted in an endotoxin-free environment from femurs of 4-to 12-week-old Balb/C mice (Harlan Laboratories). Cells were cultured for 6 days in 5% CO 2 at 371C in Dulbecco's minimum essential medium (DMEM) supplemented with 20% heat-inactivated fetal bovine serum (FBS, Gibco BRL), 50 mM 2-mercaptoethanol, 100 U/ml penicillin, 100 mg/ml streptomycin (Sigma), and 30% L-cell culture supernatant containing macrophage colony-stimulating factor. 44 During the 6 days of culture, progenitor cells expanded and differentiated into adherent bone marrow-derived macrophages. After culturing, macrophages were suspended at 41C using endotoxin-free PBS without calcium and magnesium, centrifuged and washed in DMEM supplemented with 10% FBS (DME-10F). Cells were seeded at various concentrations depending on the assay procedures: 1 Â 10 6 cells were plated on a 25 mm #1 glass coverslip (Corning) in a 24-well plate for fluorescence microscopy, 1 Â 10 6 cells were plated on a 35 mm uncoated dish (Nunc) in DME-10F for flow cytometry and Northern blot analyses, and 1.25 Â l0 4 cells were plated in each well of a 96-well plate for ELISA (Falcon). The replated cells were incubated at 371C for 2-12 h to adhere before each experiment.
Treatment of cells with oligonucleotides
Adherent bone marrow macrophages were washed and treated with ODNs in various delivery formulations, diluted in serum-containing media at 371C. Formulations tested were ISIS 3082, murine ICAM-1-specific ODNs, in LLO-liposomes and controls. The six control formulations tested were as follows: DME-10F alone, free unencapsulated ODNs, blank liposomes, LLO-liposomes with no ODNs, ODNs in liposomes containing no LLO, and control ODN sequences such as ISIS 8997 or 2302 in LLO-liposomes. After ODN treatment, cells were washed three times and chased in DME-10F for various durations, typically for 0.5 h, at 371C. After chase, macrophages were activated at 371C with 100 U/ml of interferon-g, (IFN-g, Genzyme Corporation) and 100 ng/ml of lipopolysaccharide (LPS, List Biological Laboratories, Inc.) for 8 and 2 h to observe maximal upregulation of ICAM-1 protein and mRNA, respectively.
Cytotoxicity assay (lactate dehydrogenase release)
The cytotoxicity of liposomal formulations was monitored using the lactate dehydrogenase (LDH) toxicology assay kit (Sigma). Briefly, cells were pulsed for 2 h with various liposomal formulations, washed, and chased for 2 h. After chase, cells were lysed with 2% Triton X-100, and a standard curve was generated by serially diluting the Triton-lysate samples. The LDH release into the supernatant was monitored at four separate timepoints: prior to liposome treatment, after liposome treatment, after chase, and after lysis. The cytotoxicity was calculated as a percentage of the total LDH release.
Visualization of oligonucleotide trafficking by fluorescence microscopy
The ability of LLO to deliver ODNs to the cytosol and nucleus was monitored in live cells by directly visualizing the subcellular distribution of fluorescently labeled ODNs. Carboxyfluorescein-labeled murine ICAM-1-specific ODNs (1 mg/ml) co-encapsulated with Texas Redlabeled dextrans (70 kDa, 0.3 mg/ml, Molecular Probes) in two liposomal formulations, with or without LLO, were incubated with adherent macrophages in serumcontaining media at 371C for 2 and 7 h. After ODN treatment, cells were washed three times and then chased for 0.5 h in DME-10F. After chase, cells were washed three times with Ringer's solution, pH 7.4 and mounted on a temperature-controlled stage maintained at 371C. Subcellular distribution of fluorescein-labeled ODNs and Texas Red-labeled dextrans was concurrently monitored in live macrophages. Cells were analyzed using an Axiovert 135 TV inverted microscope (Carl Zeiss Inc.) equipped with a 100 W mercury arc and halogen lamp, Â 100 oil immersion objective lenses, an excitation filter wheel alternating between 490 and 570 nm, and a long bandpass ! 520 nm emission filter. Cells were photographed using a cooled CCD camera (Roper Scientific). Three images were taken for each cell: phase contrast image, 490 nm image for fluoresceinlabeled ODN detection, and 570 nm image for Texas Redlabeled dextran detection. Images were analyzed using the MetaMorph Image Analysis software.
Quantitation of ICAM-1 by ELISA
The cell surface expression of ICAM-1 protein was quantified using ELISA. After treatment, adherent cells were washed, fixed with 1% paraformaldehyde, incubated with biotin-conjugated hamster anti-mouse CD54 (ICAM-1) monoclonal antibody (PharMingen) and then incubated with alkaline phosphatase-conjugated streptavidin (PharMingen). The substrate for alkaline phosphatase, p-nitrophenyl phosphate in diethanolamine (Sigma), was added and the absorbance of the developed phosphatase reaction product was measured at 405 nm using a microplate reader (Molecular Devices E max).
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Immuno-detection of cell surface ICAM-1 expression by flow cytometry Flow cytometric analysis was performed in order to determine whether ODNs delivered in LLO-liposomes reached the cytosolic targets and specifically inhibited the upregulated expression of target protein in activated macrophages. Cells were treated with various ODN formulations for 2 h in serum-containing media and washed with DMEM supplemented with 2% FBS. Adherent cells were incubated at 371C with trypsin/ EDTA for 1 min and suspended with minimal cell damage and no reduction in the expressed cell surface ICAM-1. The cell suspension was incubated with hamster anti-mouse (CD54) ICAM-1-specific mAb conjugated with fluorescein isothiocyanate (FITC, PharMingen) at 41C for 45 min. Polyclonal hamster IgG conjugated with FITC (PharMingen) was used as the control antibody for monitoring nonspecific ICAM-1 labeling in flow cytometry. The fluorescence intensity for the cell suspension was measured using a Coulter Epics Elite ESP flow cytometer in conjunction with the Elite acquisition software (Beckman Coulter).
Quantitation of ICAM-1 mRNA by Northern blot analysis
Northern blot analysis was performed to determine whether ODNs delivered in LLO-liposomes reached the cytosolic targets and specifically inhibited the upregulated expression of target mRNA. Cells were treated with various ODN formulations for 2 h and washed with Hanks Balanced Salt Solution (HBSS, Gibco BRL) and lysed in guanidinium thiocyanate using the RNAqueous Phenol-Free Total RNA Isolation Kit (Ambion). The total extracted RNA concentration and purity were determined spectrophotometrically by measuring the absorbance at 260 nm and by the 260/280 nm quotient, respectively. RNA samples were separated electrophoretically using a 1% agarose-formaldehyde gel with ethidium bromide. The RNA bands were transferred and crosslinked using ultraviolet light to a nylon membrane (Hybond-N, Amersham Pharmacia Biotech). Blots were prehybridized with Zip/Hyb solution (Ambion) and probed with ICAM-1 cDNA (American Type Culture Collection) labeled with 32 P-dCTP utilizing the Rediprime II random prime labeling kit (Amersham Pharmacia Biotech). Blots were exposed to an X-Omat Kodak film with a BioMax TranScreen-HE intensifying screen (Kodak) and the bands were quantified using MetaMorph Image Analysis software. Blots were then stripped and reprobed for a housekeeping gene using murine glyceraldehyde-3-phosphate dehyrodgenase (GAPDH) probe (Ambion), which serves as a control for mRNA expression.
